145 related articles for article (PubMed ID: 17934981)
21. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
Ghobrial IM; Otteman LA; White WL
N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
[No Abstract] [Full Text] [Related]
22. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
23. Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.
Verma S; Frambach GE; Seilstad KH; Nuovo G; Porcu P; Magro CM
J Cutan Pathol; 2005 Aug; 32(7):474-83. PubMed ID: 16008691
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab (Campath 1-H).
Schaal AD
Clin J Oncol Nurs; 2005 Oct; 9(5):630-2. PubMed ID: 16235592
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
26. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL
J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576
[TBL] [Abstract][Full Text] [Related]
27. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
28. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H
Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
Gibbs SD; Herbert KE; McCormack C; Seymour JF; Prince HM
Eur J Haematol; 2004 Dec; 73(6):447-9. PubMed ID: 15522069
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
Yoshino T; Nakamura S; Matsuno Y; Ochiai A; Yokoi T; Kitadai Y; Suzumiya J; Tobinai K; Kobayashi Y; Oda I; Mera K; Ohtsu A; Ishikura S
Cancer Sci; 2006 Feb; 97(2):163-6. PubMed ID: 16441428
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
[No Abstract] [Full Text] [Related]
32. Mycobacterium haemophilum infection after alemtuzumab treatment.
Kamboj M; Louie E; Kiehn T; Papanicolaou G; Glickman M; Sepkowitz K
Emerg Infect Dis; 2008 Nov; 14(11):1821-3. PubMed ID: 18976587
[No Abstract] [Full Text] [Related]
33. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
34. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
[No Abstract] [Full Text] [Related]
35. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Orlandi EM; Baldanti F; Citro A; Pochintesta L; Gatti M; Lazzarino M
Haematologica; 2008 Nov; 93(11):1758-60. PubMed ID: 18790800
[No Abstract] [Full Text] [Related]
36. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
37. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
Lundin J; Hagberg H; Repp R; Cavallin-Ståhl E; Fredén S; Juliusson G; Rosenblad E; Tjønnfjord G; Wiklund T; Osterborg A
Blood; 2003 Jun; 101(11):4267-72. PubMed ID: 12543862
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
